Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 5/20 | 0.33 |
| ▸ | JAK1 | P23458 | 5/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2799068 | 0.94 | MC4R (0.37) | MC4RALDH1A1RORCJAK2JAK1 | |
| SCHEMBL13308426 | 0.92 | MC4R (0.36) | MC4RALDH1A1RORCJAK2JAK1 | |
| SCHEMBL3353154 | 0.92 | MC4R (0.36) | MC4RALDH1A1RORCJAK2JAK1 | |
| SCHEMBL3352280 | 0.91 | MC4R (0.36) | MC4RALDH1A1RORCJAK2JAK1 | |
| SCHEMBL3358997 | 0.91 | MC4R (0.36) | MC4RALDH1A1RORCJAK2JAK1 | |
| SCHEMBL3356511 | 0.91 | MC4R (0.36) | MC4RALDH1A1RORCJAK2JAK1 | |
| SCHEMBL3355017 | 0.90 | MC4R (0.35) | MC4RALDH1A1RORCJAK2JAK1 | |
| SCHEMBL3354406 | 0.90 | MC4R (0.35) | MC4RALDH1A1RORCJAK2JAK1 | |
| SCHEMBL13308309 | 0.90 | MC4R (0.35) | MC4RALDH1A1RORCJAK2JAK1 | |
| SCHEMBL3354692 | 0.90 | MC4R (0.36) | MC4RALDH1A1RORCJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | KHAMRAI UTTAM | 2010-06-17 | — | — | US | disclosed |
| WO-2010068881-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152160-A1 | NOVEL BENZODIOXANE AND BENZOXAZINE DERIVATIVES USEFUL AS CC CHEMOKINE RECEPTOR LIGANDS | CCR1, CCR4, CCR5 | MC4R 1326/4885ALDH1A1 903/4885SMN1; SMN2 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.